Absci Corporation Common Stock (ABSI)
Stock · NASDAQ · Health Care
$8.25as of 10/16/2026
Price chart
Active signals
ABSI Signal Track Record
How signals performed across all stocks →What ABSI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +0.3% | 51% | September 17, 2026 |
| Bollinger Band Breakout | 29 | -8.8% | 31% | September 22, 2026 |
| Bollinger Band BreakdownActive now | 19 | +3.5% | 68% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -2.5% | 50% | April 2, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 140
- Website
- www.absci.com/
Fundamentals
- 1-day range
- $8.12$8.95
- Market cap
- $1.29B
- P/E (trailing)
- —
- P/E (forward)
- -12.22
- EPS (trailing)
- $-0.80
- Dividend yield
- —
- Beta
- 2.17
- Avg. volume
- 3.37M
How Absci Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Absci Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
- MXCTMaxCyte Inc. Common Stock$1.3▲ 0.00%Market cap $118.91MP/E —$0.643$1.87
- ONMDOneMedNet Corp Class A Common Stock$4.51▼ 5.05%Market cap $37.18MP/E —$4.9$42.2
- BIAFbioAffinity Technologies Inc. Common Stock$3.73▼ 5.81%Market cap $4.12MP/E —$4.56$80.7
- ISPCiSpecimen Inc. Common Stock$0.917▼ 10.97%Market cap $3.35MP/E —$1.02$36.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
| MXCT MaxCyte Inc. Common Stock | $118.91M | — | $1.3 | ▲ 0.00% | $0.643$1.87 |
| ONMD OneMedNet Corp Class A Common Stock | $37.18M | — | $4.51 | ▼ 5.05% | $4.9$42.2 |
| BIAF bioAffinity Technologies Inc. Common Stock | $4.12M | — | $3.73 | ▼ 5.81% | $4.56$80.7 |
| ISPC iSpecimen Inc. Common Stock | $3.35M | — | $0.917 | ▼ 10.97% | $1.02$36.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Keybanc Maintains Overweight on Absci, Raises Price Target to $20benzinga · 10/16/2026
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?Yahoo · 10/7/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for EndometriosisYahoo · 9/24/2026
- Needham Reiterates Buy on Absci, Maintains $11 Price TargetBenzinga · 9/23/2026
- Absci (ABSI) Stock Looks Expensive Against Its Book ValueYahoo · 9/22/2026
- Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley ConferenceYahoo · 9/21/2026
- Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On ThursdayBenzinga · 9/17/2026
Insider Activity
Insider Actions →- Zachariah Jonasson · August 31, 2026 · Tax Withholding8.3K @ $8.71
- Somaratne Ransi Mudalinayake · August 3, 2026 · Grant383.0K
- Mary T. Szela · June 30, 2026 · Buy12.9K @ $11.54
- Sean McClain · June 24, 2026 · Tax Withholding59.9K @ $10.08
- Karen K. McGinnis · June 4, 2026 · Grant39.8K
- Karen K. McGinnis · June 4, 2026 · Grant10.1K
- Menelas N. Pangalos · June 4, 2026 · Grant39.8K
- Mary T. Szela · June 4, 2026 · Grant33.2K
- Mary T. Szela · June 4, 2026 · Grant8.4K
- Menelas N. Pangalos · June 4, 2026 · Grant10.1K
- VAN HOUTEN FRANS · June 4, 2026 · Grant39.8K
- VAN HOUTEN FRANS · June 4, 2026 · Grant10.1K
- Joseph Sirosh · June 4, 2026 · Grant39.8K
- Joseph Sirosh · June 4, 2026 · Grant10.1K
- Mary T. Szela · June 4, 2026 · Grant39.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 121.41M
- Total value held
- $363.85M
- Institutional holders
- 162
- Unknown22.55M
- Unknown13.73M
- Unknown11.26M
- Unknown8.25M
- Unknown7.32M
- Unknown5.71M
- Unknown3.34M
- Unknown3.30M
- Unknown3.18M
- Unknown2.90M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ABSI to Report Q3 2026 Results on Nov 12, Shares Drop
Absci will announce its third‑quarter 2026 financials on Nov. 12. The company’s shares fell after a recent analyst note that the stock trades near the lower end of its 52‑week range and a new price target of $14.50. The drop follows a whale‑level buying alert and a broader market move higher for several large names. The upcoming earnings release may clarify the company’s outlook.
ABSI to Report Q3 2026 Results on Nov 12, Shares Drop. Absci will announce its third‑quarter 2026 financials on Nov. 12. The company’s shares fell after a recent analyst note that the stock trades near the lower end of its 52‑week range and a new price target of $14.50. The drop follows a whale‑level buying alert and a broader market move higher for several large names. The upcoming earnings release may clarify the company’s outlook.